November 30, 2022 7:47am
Indications: 1 Positive Indication and 2 Negative Indications
News: bluebird bio (BLUE +$0.26 or +3.40% to $7.65) has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $102 million.
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.
I don’t seek fame, do podcasts or give speeches; what I do is write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!
8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.05% or (+18 points), S&P futures are UP +0.16% or (+6 points) and NASDAQ futures are UP +0.31% or (+35 points) early in the pre-open – so far,
Stock futures rose Wednesday,
European markets are positive,
Asia-Pacific shares were mostly higher.
Henry’omics:
We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes were mixed on Tuesday, ahead of an upcoming speech by U.S. Fed Chair Powell that could provide hints about magnitude of future interest rate hikes.
The Dow closed UP +1.02 points (0.00%), the S&P close DOWN -6.36 points (-0.16%) while the Nasdaq closed DOWN -65.72 points (-0.59%)
Economic Data Docket: the October JOLTS report will show job openings, with Fed chief Jerome Powell speaking later in the day. On Thursday, the PCE price index, the Fed's favorite inflation gauge, will be released, along with jobless claims and the ISM manufacturing index. The November jobs report is due on Friday. Tame inflation and labor data will reinforce expectations for a smaller 50-basis-point Fed rate hike on Dec. 14 and perhaps signal further slowing in the pace of rate increases early next year.
Tuesday’s (11/29) … RegMed Investors’ (RMi) closing bell: “the pendulum swung. As the sector’s oversold popped with “ruled’ algorithms being their friend until the closing hour” … https://www.regmedinvestors.com/articles/12720
Ebb and flow:
Q4 – November -1 holiday, 14 negative and 7 positive closes
· October -1 neutral, 11 positive and 9 negative closes
Q3/22 –
· September – 1 holiday, 10 positive and 11 negative closes
· August – 1 neutral, 11 positive and 11 negative closes
· July - 1 holiday, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Positive indication:
bluebird bio (BLUE) closed up +$0.28 to $7.65 with a positive =$0.26 or +4.40% pre-open indication,
Negative Indication:
Intellia Therapeutics (NTLA) closed down again -$0.26 to $48.00 after Monday’s -$1.42 Friday’s -$0.21 with a negative -$1.05 or -2.19% pre-open indication
Ultragenyx RARE) closed up +$0.27 to $35.67 after Monday’s -$0.32 after Friday’s +$0.42 with a negative -$0.67 or -1.88% pre-open indication,
The BOTTOM LINE: I try to keep it simple and short!
In the very short term, investors may want to be cautious about making new buys. The market and sector face a big technical test with inflation and jobs reports likely to play a key role in how that plays out.
“While it's fine putting money to work in the current stock market, keep your exposure on the conservative side with small positions to start. Just because the stock market is in a confirmed uptrend doesn't mean you have to be 100% invested. And don't be afraid to take a 10% gain if you have it, given the choppy nature of the market.” <IBD>
Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.
Reiterating, “The real question that should be asked is how many companies are at the end of sentiments … leash? I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”.
Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
